---
title: "&#x1F535; Blood pressure"
layout: default
nav_order: 110
seo:
  headline: "Blood pressure"
  name: "Blood pressure"
  date_modified: "2025-09-24T06:46:00.933275Z"
---

# Blood pressure

Updated September 24, 2025.



## &#x1F7E2; CONTEC 08A-VET Veterinary/Animal Blood Pressure Monitor

![CONTEC 08A-VET Veterinary/Animal Blood Pressure Monitor](https://contechealth.com/cdn/shop/products/20_1024x1024.jpg){: style="max-height: 144px; width: auto; float: right; margin-left: 1em;" }

[**Blood pressure**]({% link docs/blood-pressure.md %})
{: .label }
[**Monitoring**]({% link docs/monitoring.md %})
{: .label }

View on <a href="https://www.amazon.com/dp/B075CVM9R6/ref=nosim?tag=ckdcatsupplies-20" class="external" target="_blank">Amazon&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a> &#x1f4b2; &#124; <a href="https://contechealth.com/collections/vet-blood-pressure-monitor/products/contec08a-vet-electronic-sphygmomanometer" class="external" target="_blank">Contec Health&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

{: .lunasays-title }
> &#x1F63A; Luna Says
>
> Keeping tabs on blood pressure is super important for a CKD kitty like me! This device, plus regular vet visits, help make sure my blood pressure is just right. If you're seeing a lot of "weak signal" or "timeout" errors, try replacing the cuff.

* * *



## &#x1F7E2; CONTEC Neonate Cuff 6 to 11 cm

![CONTEC Neonate Cuff 6 to 11 cm](https://contechealth.com/cdn/shop/products/5__E_1024x1024.jpg){: style="max-height: 144px; width: auto; float: right; margin-left: 1em;" }

[**Blood pressure**]({% link docs/blood-pressure.md %})
{: .label }
[**Monitoring**]({% link docs/monitoring.md %})
{: .label }

View on <a href="https://contechealth.com/products/neonate-cuff-6-to-11-cm-arm-single-tube-reusable-cuff-for-patient-nibp-monitor?variant=41026112454806" class="external" target="_blank">Contec Health&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

{: .lunasays-title }
> &#x1F63A; Luna Says
>
> This may ship from overseas and take a while to arrive. If the small animal cuff is unavailable, this can be substituted.

* * *



## &#x1F7E2; CONTEC Small Animal Cuff 6 to 11 cm

![CONTEC Small Animal Cuff 6 to 11 cm](https://contechealth.com/cdn/shop/files/04_63247d1b-d7e4-4866-b02a-06da28dd5e24_1024x1024.jpg){: style="max-height: 144px; width: auto; float: right; margin-left: 1em;" }

[**Blood pressure**]({% link docs/blood-pressure.md %})
{: .label }
[**Monitoring**]({% link docs/monitoring.md %})
{: .label }

View on <a href="https://contechealth.com/collections/accessories-for-upper-arm-blood-pressure-monitor/products/contec-small-animal-cuff-6-11-cm-single-tube-cuff-for-nibp-blood-pressure-monitor-contec08a-vet" class="external" target="_blank">Contec Health&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

{: .lunasays-title }
> &#x1F63A; Luna Says
>
> This may ship from overseas and take a while to arrive. The neonate cuff can be substituted if this is unavailable.

* * *



## &#x1F7E2; Generic Atenolol Compounded Oral Oil Liquid

![Generic Atenolol Compounded Oral Oil Liquid](https://image.chewy.com/is/image/catalog/274546_MAIN._AC_SL600_V1638919327_.jpg){: style="max-height: 144px; width: auto; float: right; margin-left: 1em;" }

[**Blood pressure**]({% link docs/blood-pressure.md %})
{: .label }
[**Drugs**]({% link docs/drugs.md %})
{: .label }
[**Heart**]({% link docs/heart.md %})
{: .label }

View on <a href="https://www.chewy.com/dp/300965" class="external" target="_blank">Chewy&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

<details markdown="block">
<summary>References and resources</summary>

1. _"This study failed to identify an effect of subclinical HCM on owner assessed QOL or activity, or a treatment effect of atenolol on these variables at the dosage evaluated. These findings do not support a treatment benefit of atenolol for the goal of symptom reduction in cats with subclinical HCM."_ &mdash;  Coleman AE, DeFrancesco TC, Griffiths EH, Lascelles BDX, Kleisch DJ, Atkins CE, Keene BW. Atenolol in cats with subclinical hypertrophic cardiomyopathy: a double-blind, placebo-controlled, randomized clinical trial of effect on quality of life, activity, and cardiac biomarkers. J Vet Cardiol. 2020 Aug;30:77-91. doi:<a href="https://doi.org/10.1016/j.jvc.2020.06.002" class="external" target="_blank">10.1016/j.jvc.2020.06.002&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a> (retrieved 2025-05-08)
1.  Drug Handout: Atenolol. CVCA. 2016. <a href="https://www.cvcavets.com/drug-handouts/atenolol/" class="external" target="_blank">https://www.cvcavets.com/drug-handouts/atenolol/&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1. _"If a cat is receiving beta-blockers (e.g., for previously diagnosed HCM with LVOTO), the dose should be carefully down-titrated or even stopped after a few weeks. This is because the intense neuroendocrine activation of CHF includes increased sympathetic drive to maintain cardiac output; beta-blockade may prevent some of this compensatory effort. However, the decision about discontinuing beta-blockers depends on each individual case (e.g., if there is significant LVOTO). Beta-blockers should never be started in a cat presenting with uncontrolled CHF; an interim analysis of heart failure treatments indicated significantly reduced survival in cats receiving this class of drug."_ &mdash;  Dukes-McEwan J, Partington C. Management of the cat with heart failure. Royal Canin Academy web site. 2022. <a href="https://academy.royalcanin.com/en/veterinary/management-of-the-cat-with-heart-failure" class="external" target="_blank">https://academy.royalcanin.com/en/veterinary/management-of-the-cat-with-heart-failure&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a> (retrieved 2025-05-08)
1. _"...at interim analysis, there was little evidence to suggest that chronic administration of furosemide plus either atenolol, dilacor, or enalapril at doses specified, provided any major advantage in clinical outcome versus administration of furosemide alone."_ &mdash;  Fox PR. Prospective, double-blinded, multicenter evaluation of chronic therapies for feline diastolic heart failure: interim analysis. Research Abstract Program of the 21st Annual ACVIM Forum Charlotte, NC, June 4-7, 2003. Journal of Veterinary Internal Medicine, 17: 398-399. doi:<a href="https://doi.org/10.1111/j.1939-1676.2003.tb02465.x" class="external" target="_blank">10.1111/j.1939-1676.2003.tb02465.x&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a> (retrieved 2025-05-08)
1.  Jensen J, Henik RA, Brownfield M, Armstrong J. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease. Am J Vet Res. 1997 May;58(5):535-40. doi:<a href="https://doi.org/10.2460/ajvr.1997.58.05.535" class="external" target="_blank">10.2460/ajvr.1997.58.05.535&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1. _"Atenolol administration did not decrease NT-proBNP or cTnI concentrations in cats with severe left ventricular hypertrophy caused by hypertrophic cardiomyopathy. These results suggest that atenolol did not decrease myocardial ischemia and myocyte death in these cats."_ &mdash;  Jung, S.W. and Kittleson, M.D. (2011), The Effect of Atenolol on NT-proBNP and Troponin in Asymptomatic Cats with Severe Left Ventricular Hypertrophy because of Hypertrophic Cardiomyopathy: A Pilot Study. Journal of Veterinary Internal Medicine, 25: 1044-1049. doi:<a href="https://doi.org/10.1111/j.1939-1676.2011.0754.x" class="external" target="_blank">10.1111/j.1939-1676.2011.0754.x&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a> (retrieved 2025-05-08)
1.  Macgregor JM, Rush JE, Rozanski EA, Boothe DM, Belmonte AA, Freeman LM. Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats. Am J Vet Res. 2008 Jan;69(1):39-44. doi:<a href="https://doi.org/10.2460/ajvr.69.1.39" class="external" target="_blank">10.2460/ajvr.69.1.39&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Ogawa M, Kawamura A, Akabane R, Sakatani A, Miyakawa H, Hsu H-H, et al. Effects of ivabradine and atenolol on heart rate and heart rate variability in healthy cats over a 24 h period: a pilot study. Vet Rec Open. 2022; 9:e28. doi:<a href="https://doi.org/10.1002/vro2.28" class="external" target="_blank">10.1002/vro2.28&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Qui√±ones M, Dyer DC, Ware WA, Mehvar R. Pharmacokinetics of atenolol in clinically normal cats. Am J Vet Res. 1996 Jul;57(7):1050-3. doi:<a href="https://doi.org/10.2460/ajvr.1996.57.07.1050" class="external" target="_blank">10.2460/ajvr.1996.57.07.1050&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Riesen, S.C., Schober, K.E., Cervenec, R.M. and Bonagura, J.D. (2011), Comparison of the Effects of Ivabradine and Atenolol on Heart Rate and Echocardiographic Variables of Left Heart Function in Healthy Cats. Journal of Veterinary Internal Medicine, 25: 469-476. doi:<a href="https://doi.org/10.1111/j.1939-1676.2011.0705.x" class="external" target="_blank">10.1111/j.1939-1676.2011.0705.x&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1. _"Our study failed to demonstrate an effect of atenolol on 5-year survival in cats with preclinical HCM."_ &mdash;  Schober KE, Zientek J, Li X, Fuentes VL, Bonagura JD. Effect of treatment with atenolol on 5-year survival in cats with preclinical (asymptomatic) hypertrophic cardiomyopathy. J Vet Cardiol. 2013 Jun;15(2):93-104. doi:<a href="https://doi.org/10.1016/j.jvc.2013.03.003" class="external" target="_blank">10.1016/j.jvc.2013.03.003&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a> (retrieved 2025-05-08)
1.  Keisuke SUGIMOTO, Takuma AOKI, Yoko FUJII, Effects of atenolol on left atrial and left ventricular function in healthy cats and in cats with hypertrophic cardiomyopathy, Journal of Veterinary Medical Science, 2020, Volume 82, Issue 5, Pages 546-552. doi:<a href="https://doi.org/10.1292/jvms.19-0670" class="external" target="_blank">10.1292/jvms.19-0670&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Waterman M (2018). Pharmacodynamic evaluation of beta-blockade associated with atenolol in healthy dogs. Master's Thesis, Virginia Polytechnic Institute and State University. <a href="http://hdl.handle.net/10919/97339" class="external" target="_blank">http://hdl.handle.net/10919/97339&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Wilkinson R. Do beta-blockers have a place in the treatment of feline hypertrophic cardiomyopathy (HCM)? 2021. <a href="https://www.vetpracticesupport.com/the-use-of-beta-blockers-in-feline-hypertrophic-cardiomyopathy-hcm/" class="external" target="_blank">https://www.vetpracticesupport.com/the-use-of-beta-blockers-in-feline-hypertrophic-cardiomyopathy-hcm/&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a> (retrieved 2025-05-08)

</details>

* * *



## &#x1F7E2; Generic Telmisartan Compounded Oral Oil Liquid

![Generic Telmisartan Compounded Oral Oil Liquid](https://image.chewy.com/is/image/catalog/583926_MAIN._AC_SL600_V1659906586_.jpg){: style="max-height: 144px; width: auto; float: right; margin-left: 1em;" }

[**Blood pressure**]({% link docs/blood-pressure.md %})
{: .label }
[**Drugs**]({% link docs/drugs.md %})
{: .label }
[**Proteinuria**]({% link docs/proteinuria.md %})
{: .label }
[**Renal**]({% link docs/renal.md %})
{: .label }

View on <a href="https://www.chewy.com/dp/583926" class="external" target="_blank">Chewy&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

<details markdown="block">
<summary>References and resources</summary>

1.  Committee for Medicinal Products for Veterinary Use. CVMP assessment report for Semintra to add new strength 10 mg/ml oral solution for cats to treat systemic hypertension. European Medicines Agency. 2018. <a href="https://medicines.health.europa.eu/veterinary/es/documents/download/7b45beb0-53c0-46ab-9cd0-8f4e418a6ed6" class="external" target="_blank">https://medicines.health.europa.eu/veterinary/es/documents/download/7b45beb0-53c0-46ab-9cd0-8f4e418a6ed6&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Semintra (telmisartan oral solution) 10 mg/mL product insert. Boehringer Ingelheim Animal Health USA Inc. 2019. <a href="https://docs.boehringer-ingelheim.com/PI/Theras/Semintra_PI.pdf" class="external" target="_blank">https://docs.boehringer-ingelheim.com/PI/Theras/Semintra_PI.pdf&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9. doi:<a href="https://doi.org/10.1056/NEJMoa011161" class="external" target="_blank">10.1056/NEJMoa011161&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Coleman AE, Brown SA, Traas AM, Bryson L, Zimmering T, Zimmerman A. Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial. J Vet Intern Med. 2019; 33: 478-488. doi:<a href="https://doi.org/10.1111/jvim.15429" class="external" target="_blank">10.1111/jvim.15429&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Coleman A, Elliott J. Inhibition of the renin-angiotensin-aldosterone system in cats and dogs: The emerging role of angiotensin II receptor blockers. International Renal Interest Society (IRIS). 2022. <a href="http://www.iris-kidney.com/education/renin-anglotensin-aldosterone-system.html" class="external" target="_blank">http://www.iris-kidney.com/education/renin-anglotensin-aldosterone-system.html&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Girens R, Swift S. Telmisartan for Treating Systemic Hypertension. Today's Veterinary Practice. 2019. <a href="https://todaysveterinarypractice.com/pharmacology/telmisartan-for-treating-systemic-hypertension/" class="external" target="_blank">https://todaysveterinarypractice.com/pharmacology/telmisartan-for-treating-systemic-hypertension/&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Glaus TM, Elliott J, Herberich E, Zimmering T, Albrecht B. Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial. J Vet Intern Med. 2019; 33: 413-422. doi:<a href="https://doi.org/10.1111/jvim.15394" class="external" target="_blank">10.1111/jvim.15394&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Gordon SG, Saunders AB, Malcolm E. Angiotensin II Receptor Antagonists for Use in Animals. Merck Veterinary Manual. 2023. <a href="https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-cardiovascular-system/angiotensin-ii-receptor-antagonists-for-use-in-animals" class="external" target="_blank">https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-cardiovascular-system/angiotensin-ii-receptor-antagonists-for-use-in-animals&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005 Dec;16(12):3631-41. doi:<a href="https://doi.org/10.1681/ASN.2005050522" class="external" target="_blank">10.1681/ASN.2005050522&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19(17):3033-42. doi:<a href="https://doi.org/10.2174/1381612811319170009" class="external" target="_blank">10.2174/1381612811319170009&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60. doi:<a href="https://doi.org/10.1056/NEJMoa011303" class="external" target="_blank">10.1056/NEJMoa011303&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Sent U, G√∂ssl R, Elliott J, Syme HM, Zimmering T. Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease. J Vet Intern Med. 2015 Nov-Dec;29(6):1479-87. doi:<a href="https://doi.org/10.1111/jvim.13639" class="external" target="_blank">10.1111/jvim.13639&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-31. doi:<a href="https://doi.org/10.1001/jama.288.19.2421" class="external" target="_blank">10.1001/jama.288.19.2421&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. Drugs. 2020 Jun;80(8):797-811. doi:<a href="https://doi.org/10.1007/s40265-020-01290-3" class="external" target="_blank">10.1007/s40265-020-01290-3&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

</details>

* * *



## &#x1F7E2; SunTech Vet20 Veterinary Blood Pressure Monitor (Peacock Blue)

![SunTech Vet20 Veterinary Blood Pressure Monitor](https://www.suntechmed.com/images/products/vet20/vet20-sill-555x366.png){: style="max-height: 144px; width: auto; float: right; margin-left: 1em;" }

[**Blood pressure**]({% link docs/blood-pressure.md %})
{: .label }
[**Monitoring**]({% link docs/monitoring.md %})
{: .label }

 <a href="https://www.suntechmed.com/bp-products/veterinary-blood-pressure-monitors/suntech-vet20-veterinary-blood-pressure-monitor" class="external" target="_blank">manufacturer page&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

View on <a href="https://www.amazon.com/dp/B01N6NIBPW/ref=nosim?tag=ckdcatsupplies-20" class="external" target="_blank">Amazon&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a> &#x1f4b2;

<details markdown="block">
<summary>References and resources</summary>

1.  Cremer J, da Cunha A, Aulakh K, Liu CC, Acierno MJ. Validation of the oscillometric blood pressure monitor Vet20 SunTech in anesthetized healthy cats. Vet Anaesth Analg. 2020 May;47(3):309-314. doi:<a href="https://doi.org/10.1016/j.vaa.2019.12.007" class="external" target="_blank">10.1016/j.vaa.2019.12.007&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

</details>

* * *



## &#x1F7E2; Vmed Technology vet-dop2

![Vmed Technology vet-dop2](https://www.vmedtechnology.com/wp-content/uploads/2023/09/vet-dop2.png){: style="max-height: 144px; width: auto; float: right; margin-left: 1em;" }

Veterinary Doppler blood pressure system.

[**Blood pressure**]({% link docs/blood-pressure.md %})
{: .label }
[**Monitoring**]({% link docs/monitoring.md %})
{: .label }

 <a href="https://www.vmedtechnology.com/product/vet-dop/" class="external" target="_blank">manufacturer page&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

View on <a href="https://www.vmedtechnology.com/product/vet-dop/" class="external" target="_blank">Vmed Technology&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

* * *


# Blood pressure references and resources

1.  Committee for Medicinal Products for Veterinary Use. CVMP assessment report for Semintra to add new strength 10 mg/ml oral solution for cats to treat systemic hypertension. European Medicines Agency. 2018. <a href="https://medicines.health.europa.eu/veterinary/es/documents/download/7b45beb0-53c0-46ab-9cd0-8f4e418a6ed6" class="external" target="_blank">https://medicines.health.europa.eu/veterinary/es/documents/download/7b45beb0-53c0-46ab-9cd0-8f4e418a6ed6&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Hypertension, chronic kidney disease and the renin-angiotensin-aldosterone system (2020). American Animal Hospital Association. <a href="https://www.aaha.org/wp-content/uploads/globalassets/05-pet-health-resources/critical-connections_web.pdf" class="external" target="_blank">https://www.aaha.org/wp-content/uploads/globalassets/05-pet-health-resources/critical-connections_web.pdf&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Acierno MJ, Brown S, Coleman AE, et al. ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2018; 32: 1803‚Äì1822. doi:<a href="https://doi.org/10.1111/jvim.15331" class="external" target="_blank">10.1111/jvim.15331&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Adin D, Atkins C, Domenig O, Glahn C, DeFrancesco T, Meurs K. Evaluation of Renin-Angiotensin-Aldosterone System Components and Enzymes in Systemically Hypertensive Cats Receiving Amlodipine. Animals (Basel). 2023 Nov 10;13(22):3479. doi:<a href="https://doi.org/10.3390/ani13223479" class="external" target="_blank">10.3390/ani13223479&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Brown SA, Brown CA, Jacobs G, Stiles J, Hendi RS, Wilson S. Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency. Am J Vet Res. 2001 Mar;62(3):375-83. doi:<a href="https://doi.org/10.2460/ajvr.2001.62.375" class="external" target="_blank">10.2460/ajvr.2001.62.375&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Cannon MJ, Brett J. Comparison of how well conscious cats tolerate blood pressure measurement from the radial and coccygeal arteries. J Feline Med Surg. 2012 Dec;14(12):906-9. doi:<a href="https://doi.org/10.1177/1098612X12455023" class="external" target="_blank">10.1177/1098612X12455023&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Carter J. Hypertensive ocular disease in cats: A guide to fundic lesions to facilitate early diagnosis. Journal of Feline Medicine and Surgery. 2019;21(1):35-45. doi:<a href="https://doi.org/10.1177/1098612X18818668" class="external" target="_blank">10.1177/1098612X18818668&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Coleman AE, Brown SA, Traas AM, Bryson L, Zimmering T, Zimmerman A. Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial. J Vet Intern Med. 2019; 33: 478-488. doi:<a href="https://doi.org/10.1111/jvim.15429" class="external" target="_blank">10.1111/jvim.15429&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Coleman A, Elliott J. Inhibition of the renin-angiotensin-aldosterone system in cats and dogs: The emerging role of angiotensin II receptor blockers. International Renal Interest Society (IRIS). 2022. <a href="http://www.iris-kidney.com/education/renin-anglotensin-aldosterone-system.html" class="external" target="_blank">http://www.iris-kidney.com/education/renin-anglotensin-aldosterone-system.html&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Garcia Marrero TM, Ward JL, Tropf MA, Bourgois-Mochel A, Guillot E, Domenig O, Yuan L, Kundu D, Mochel JP. Effect of amlodipine on the circulating renin-angiotensin-aldosterone system in healthy cats. J Vet Intern Med. 2024 Mar-Apr;38(2):913-921. doi:<a href="https://doi.org/10.1111/jvim.17006" class="external" target="_blank">10.1111/jvim.17006&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Girens R, Swift S. Telmisartan for Treating Systemic Hypertension. Today's Veterinary Practice. 2019. <a href="https://todaysveterinarypractice.com/pharmacology/telmisartan-for-treating-systemic-hypertension/" class="external" target="_blank">https://todaysveterinarypractice.com/pharmacology/telmisartan-for-treating-systemic-hypertension/&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Glaus TM, Elliott J, Herberich E, Zimmering T, Albrecht B. Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial. J Vet Intern Med. 2019; 33: 413-422. doi:<a href="https://doi.org/10.1111/jvim.15394" class="external" target="_blank">10.1111/jvim.15394&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Gordon SG, Saunders AB, Malcolm E. Angiotensin II Receptor Antagonists for Use in Animals. Merck Veterinary Manual. 2023. <a href="https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-cardiovascular-system/angiotensin-ii-receptor-antagonists-for-use-in-animals" class="external" target="_blank">https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-cardiovascular-system/angiotensin-ii-receptor-antagonists-for-use-in-animals&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Hampton A, Ford A, Cox RE 3rd, Liu CC, Koh R. Effects of music on behavior and physiological stress response of domestic cats in a veterinary clinic. J Feline Med Surg. 2020 Feb;22(2):122-128. doi:<a href="https://doi.org/10.1177/1098612X19828131" class="external" target="_blank">10.1177/1098612X19828131&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005 Dec;16(12):3631-41. doi:<a href="https://doi.org/10.1681/ASN.2005050522" class="external" target="_blank">10.1681/ASN.2005050522&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Jepson, R.E., Syme, H.M. and Elliott, J. (2014), Plasma Renin Activity and Aldosterone Concentrations in Hypertensive Cats with and without Azotemia and in Response to Treatment with Amlodipine Besylate. J Vet Intern Med, 28: 144-153. doi:<a href="https://doi.org/10.1111/jvim.12240" class="external" target="_blank">10.1111/jvim.12240&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19(17):3033-42. doi:<a href="https://doi.org/10.2174/1381612811319170009" class="external" target="_blank">10.2174/1381612811319170009&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Kothari N, Ganguly B (2014). Potential Drug-Drug Interactions among Medications Prescribed to Hypertensive Patients. J Clin of Diagn Res. 8(11), HC01-HC04. doi:<a href="https://doi.org/10.7860/JCDR/2014/10032.5091" class="external" target="_blank">10.7860/JCDR/2014/10032.5091&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Lalor SM, Connolly DJ, Elliott J, Syme HM. Plasma concentrations of natriuretic peptides in normal cats and normotensive and hypertensive cats with chronic kidney disease. J Vet Cardiol. 2009 May;11 Suppl 1:S71-9. doi:<a href="https://doi.org/10.1016/j.jvc.2009.01.004" class="external" target="_blank">10.1016/j.jvc.2009.01.004&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Lawson JS, Jepson RE. Feline comorbidities: The intermingled relationship between chronic kidney disease and hypertension. Journal of Feline Medicine and Surgery. 2021;23(9):812-822. doi:<a href="https://doi.org/10.1177/1098612X211037872" class="external" target="_blank">10.1177/1098612X211037872&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Linek J. Iris aneurysm in feline hypertensive oculopathy. Vet Ophthalmol. 2020; 23: 436-441. doi:<a href="https://doi.org/10.1111/vop.12738" class="external" target="_blank">10.1111/vop.12738&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Maggio F, DeFrancesco TC, Atkins CE, Pizzirani S, Gilger BC, Davidson MG. Ocular lesions associated with systemic hypertension in cats: 69 cases (1985-1998). J Am Vet Med Assoc. 2000 Sep 1;217(5):695-702. doi:<a href="https://doi.org/10.2460/javma.2000.217.695" class="external" target="_blank">10.2460/javma.2000.217.695&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007 Jun;25(6):1105-87. doi:<a href="https://doi.org/10.1097/HJH.0b013e3281fc975a" class="external" target="_blank">10.1097/HJH.0b013e3281fc975a&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Mika MISHINA, Nobuyoshi WATANABE, Toshifumi WATANABE, Diurnal Variations of Blood Pressure in Cats, Journal of Veterinary Medical Science, 2006, Volume 68, Issue 3, Pages 243-248. doi:<a href="https://doi.org/10.1292/jvms.68.243" class="external" target="_blank">10.1292/jvms.68.243&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Quimby JM. Maropitant Use in Cats. Today's Veterinary Practice. 2020. <a href="https://todaysveterinarypractice.com/pharmacology/maropitant-use-in-cats/" class="external" target="_blank">https://todaysveterinarypractice.com/pharmacology/maropitant-use-in-cats/&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Quimby JM, Jones SE, Saffire A, et al. Assessment of the effect of gabapentin on blood pressure in cats with and without chronic kidney disease. Journal of Feline Medicine and Surgery. 2024;26(5). doi:<a href="https://doi.org/10.1177/1098612X241240326" class="external" target="_blank">10.1177/1098612X241240326&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Scansen BA. Which Drugs Can Control Systemic Arterial Hypertension in Dogs & Cats. Plumb's Therapeutics Brief. May 2016. <a href="https://assets.ctfassets.net/4dmg3l1sxd6g/j7ipcDz6lLAmgrZV2uarX/0d81ffc57d077ea4a8ad40716bc584a3/rx-solutions_which-drugs-can-control-systemic-arterial-hypertension-in-dogs--cats-28111-article.pdf" class="external" target="_blank">https://assets.ctfassets.net/4dmg3l1sxd6g/j7ipcDz6lLAmgrZV2uarX/0d81ffc57d077ea4a8ad40716bc584a3/rx-solutions_which-drugs-can-control-systemic-arterial-hypertension-in-dogs--cats-28111-article.pdf&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Sent U, G√∂ssl R, Elliott J, Syme HM, Zimmering T. Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease. J Vet Intern Med. 2015 Nov-Dec;29(6):1479-87. doi:<a href="https://doi.org/10.1111/jvim.13639" class="external" target="_blank">10.1111/jvim.13639&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Taylor SS, Sparkes AH, Briscoe K, et al. ISFM Consensus Guidelines on the Diagnosis and Management of Hypertension in Cats. Journal of Feline Medicine and Surgery. 2017;19(3):288-303. doi:<a href="https://doi.org/10.1177/1098612X17693500" class="external" target="_blank">10.1177/1098612X17693500&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Thompson J. Management of hypertension in a geriatric cat. Can Vet J. 2004 May;45(5):427-9. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC548629/" class="external" target="_blank">https://pmc.ncbi.nlm.nih.gov/articles/PMC548629/&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-31. doi:<a href="https://doi.org/10.1001/jama.288.19.2421" class="external" target="_blank">10.1001/jama.288.19.2421&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>
1.  Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. Drugs. 2020 Jun;80(8):797-811. doi:<a href="https://doi.org/10.1007/s40265-020-01290-3" class="external" target="_blank">10.1007/s40265-020-01290-3&nbsp;<svg width="18" height="18" viewBox="0 0 24 24"><use xlink:href="#svg-external-link"></use></svg></a>

* * *

<div id="disqus_thread"></div>
<script>
    var disqus_config = function () {
      this.page.url = '{{ page.url | absolute_url }}';
      this.page.identifier = '{{ page.url | absolute_url }}';
    };
    (function() {
    var d = document, s = d.createElement('script');
    s.src = 'https://ckdcatsupplies.disqus.com/embed.js';
    s.setAttribute('data-timestamp', +new Date());
    (d.head || d.body).appendChild(s);
    })();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>

* * *

&#x1F449; Product links on this page marked with a &#x1f4b2; may earn the site a modest commission.


<!-- Updated 2025-09-24 06:46:00.933275Z -->
